Inventiva S.A./€IVA
1D1W1MYTD1Y5YMAX
Capital at risk
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
- Ticker
- €IVA
- Sector
- Health
- Primary listing
- PAR
- Employees
- 73
- Headquarters
- Daix, France
- Website
- inventivapharma.com
Inventiva S.A. Metrics
BasicAdvanced
€763M
-
-€1.90
0.88
-
Price and volume
Market cap
€763M
Beta
0.88
52-week high
€6.16
52-week low
€2.89
Average daily volume
383K
Financial strength
Current ratio
3.159
Quick ratio
1.408
Long term debt to equity
-6.962
Total debt to equity
-8.095
Interest coverage (TTM)
-0.66%
Profitability
EBITDA (TTM)
-138.856
Gross margin (TTM)
99.67%
Net profit margin (TTM)
-5,237.95%
Operating margin (TTM)
-1,965.46%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
€90,000
Management effectiveness
Return on assets (TTM)
-45.08%
Return on equity (TTM)
523.99%
Valuation
Price to revenue (TTM)
89.244
Price to book
-21.88
Price to tangible book (TTM)
-21.74
Price to free cash flow (TTM)
-5.739
Free cash flow yield (TTM)
-17.42%
Free cash flow per share (TTM)
-0.563
Growth
Revenue change (TTM)
-52.03%
Earnings per share change (TTM)
-38.48%
3-year revenue growth (CAGR)
-23.99%
10-year revenue growth (CAGR)
-2.45%
3-year earnings per share growth (CAGR)
13.13%
10-year earnings per share growth (CAGR)
7.98%
Bulls say / Bears say
Inventiva finalized a comprehensive refinancing on June 2, 2026, securing up to €130 million in debt financing with BlackRock and Claret Capital Partners and issuing 27.27 million ADSs for $4.40 each, significantly bolstering its liquidity and extending its debt maturity profile to 2030 (Nasdaq).
Preliminary H1 2026 financials show €166.1 million in cash and cash equivalents and €67.8 million in short-term deposits as of June 30, up from €99.3 million at YE 2025, reflecting strong capital inflows from the June refinancing transactions (SEC).
The NATiV3 Phase 3 clinical trial reached its final 72-week visit milestone on September 2, 2026, positioning Inventiva for a topline data readout in Q4 2026 and de-risking its lead asset’s regulatory timeline (GlobeNewswire).
Net cash used in operating activities amounted to €48.7 million in H1 2026, up from €53.7 million in H1 2025, driven by increased R&D spend as the Company advances its NATiV3 Phase 3 trial (SEC).
Inventiva recorded zero revenues for the first half of 2026, highlighting its continued pre-commercial stage and complete reliance on external financing for operations (SEC).
Based on its existing cash and cash equivalents, Inventiva expects a cash runway only through Q2 2027 unless it secures additional proceeds from the uncommitted Tranche C debt and full exercise of Tranche 3 warrants, signaling potential liquidity risk (SEC).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Upcoming events
No upcoming events
Funds containing Inventiva S.A.
AllEURGBP
Fund name | Fund size | €IVA weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.02% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.02% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.